Determination of buprenorphine in human plasma by gas chromatography- positive ion chemical ionization mass spectrometry and liquid chromatography- tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 21, Issue 6, 1997, Pages 406-414

  Moody, David E ^a   Laycock, John D ^a   Spanbauer, Alan C ^a   Crouch, Dennis J ^a   Foltz, Rodger L ^a   Josephs, Jonathan L ^b,d   Amass, Leslie ^c,e   Bickel, Warren K ^c  

^a UNIVERSITY OF UTAH   (United States)

^b Thermo Finnigan   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; LIQUID CHROMATOGRAPHY; OPIATE ADDICTION; QUALITY CONTROL; TANDEM MASS SPECTROMETRY;

EID: 0030864823     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/21.6.406     Document Type: Article

References (30)

1. W.R. Martin, C.G. Eades, J.A. Thompson, R.E. Huppler, and P.E. Gilbert. The effects of morphine and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197: 517-32 (1976).
2. A. Cowan, J.W. Lewis, and I.R. MacFarlane. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60: 537-45 (1977).
3. S.L. Walsh, K.L. Preston, G.E. Bigelow, and M.L. Stitzer. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274: 361-72 (1995).
4. J.W. Lewis. Clinical pharmacology of buprenorphine in relation to its use as an analgesic. In Buprenorphine: Combatting Drug Abuse With a Unique Opioid. A. Cowan and J.W. Lewis, Eds. Wiley-Liss, New York, NY, 1995. pp 151-63.
5. W.K. Bickel, M.L. Stitzer, G.E. Bigelow, I.A. Liebson, D.R. Jasinkski, and R.E. Johnson. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin. Pharmacol. Ther. 43: 72-78 (1988).
6. R.E. Johnson, J.H. Jaffe, and P.J. Fudala. A controlled trial of buprenorphine treatment for opioid dependence. J. Am. Med. Assoc. 267: 2750-55 (1992).
7. W. Ling, D.R. Wesson, C. Charuvastra, and J. Klett. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 53: 401-407 (1996).
8. W.K. Bickel, and L. Amass. Buprenorphine treatment of opioid dependence: a review. Exp. Clin. Psychopharmacol. 3: 477-89 (1995).
9. A.J. Bartlett, J.G. Lloyd-Jones, M.J. Rance, I.R. Flockhart, G.J. Dockray, M.R.D. Bennett, and R.A. Moore. The radioimmunoassay of buprenorphine. Eur. J. Clin. Pharmacol. 18: 339-45 (1980).
10. C.W. Hand, D. Baldwin, R.A. Moore, M.C. Allen, and H.J. McQuay. Radioimmunoassay of buprenorphine with iodine label: analysis of buprenorphine and metabolites in human plasma. Ann. Clin. Biochem. 23: 47-53 (1986).
11. C.W. Hand, K.E. Ryan, S.K. Dutt, R.A. Moore, J. O'Connor, D. Talbot, and H.J. McQuay. Radioimmunoassay of buprenorphine in urine: studies in patients and in a drug clinic. J. Anal. Toxicol. 13: 100-104 (1989).
12. L. Debrabandere, M. Van Boven, and P. Daenens. Development of a radioimmunoassay for the determination of buprenorphine in biological samples. Analyst 118: 137-43 (1993).
13. L. Debrabandere, M. Van Boven, and P. Daenens. Development of a fluoroimmunoassay for the detection of buprenorphine in urine. J. Forensic Sci. 40: 250-53 (1995).
14. I.R. Tebbett. Analysis of buprenorphine by high-performance liquid chromatography. J. Chromatogr. 347: 411-13 (1985).
15. a values, and protein binding of buprenorphine. J. Pharm. Sci. 74: 515-24 (1985).
16. S.-T. Ho. Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. J. Chromatogr. 570: 339-50 (1991).
17. G. Mullersman, S. Toufflin, and H. Derendorf. HPLC analysis of buprenorphine in plasma and urine using coulometric detection. J. Pharm. Biomed. Anal. 5: 303-308 (1987).
18. L. Debrabandere, M. Van Boven, and P. Daenens. High-performance liquid chromatography with electrochemical detection of buprenorphine and its major metabolite in urine. J. Chromatogr. 564: 557-66 (1991).
19. 63Ni Electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces. J. Chromatogr. 337: 291-300 (1985).
20. G. Alemany, A. Gamundi, C. Rossello, and M.C. Nicolau. A simple thin-layer chromatographic method for the analysis of buprenorphine in urine. Biomed. Chromatogr. 10: 146-47 (1996).
21. Y. Blom, U. Bondesson, and E. Anggard. Analysis of buprenorphine and its N-dealkylated metabolite in plasma and urine by selected-ion monitoring. J. Chromatogr. 338: 89-98 (1985).
22. M. Ohtani, F. Shibuya, H. Kotaki, K. Uchino, Y. Saitoh, F. Nakagawa, and K. Nishitateno. Quantitative determination of buprenorphine and its active metabolite, norbuprenorphine, in plasma by gas chromatography-chemical ionization mass spectrometry. J. Chromatogr. 487: 469-75 (1989).
23. J.J. Kuhlman, Jr., J. Magluilo, Jr., E. Cone, and B. Levine. Simultaneous assay of buprenorphine and norbuprenorphine by negative chemcial ionization tandem mass spectrometry. J. Anal. Toxicol. 20: 229-35 (1996).
24. A. Tracqui, P. Kintz, and P. Mangin. HPLC/MS determination of buprenorphine and norbuprenorphine in biological fluids and hair samples. J. Forensic Sci. 42: 111-14 (1997).
25. H. Hoja, P. Marquet, B. Verneuil, H. Lotfi, J.-L. Dupuy, and G. Lachatre. Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 21: 160-65 (1997).
26. L. Amass, W.K. Bickel, J.P. Crean, N. Peltry, and S.T. Higgins. Buprenorphine blockade of hydromorphone across three buprenorphine dosing schedules. Abstract. NIDA Res. Monogr. 162: 272 (1996).
27. J.J. Kuhlman, Jr., S. Lalani, J. Magluilo, Jr., B. Levine, W.D. Darwin, R.E. Johnson, and E.J. Cone. Human pharmacokinetics of intravenous, subligual, and buccal buprenorphine. J. Anal. Toxicol. 20: 369-78 (1996).
28. V.P. Shah, K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly, A. Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, R.D. McDowall, K.A. Pittman, and S. Spector. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 81: 309-12 (1992).
29. E.J. Cone, C.W. Gorodetzky, W.D. Darwin, and W.F. Buchwald. Stability of the 6,14-endo-ethanotetrahydrooripavine analgesics: acid-catalyzed rearrangement of buprenorphine. J. Pharm. Sci. 73: 243-46 (1984).
30. J.L. Laycock, A.C. Spanbauer, R.L. Foltz, D.E. Moody, and D.J. Crouch. The determination of buprenorphine and naloxone in human plasma by LC/MS/MS. Procedings of the 45th ASMS Conferance on Mass spectrometry and Allied Topics, Palm Springs, CA, June 1997.